NanoViricides (NYSE:NNVC) Cut to Sell at StockNews.com

NanoViricides (NYSE:NNVC) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

NanoViricides Stock Performance

NYSE NNVC opened at $1.37 on Monday. NanoViricides has a one year low of $1.00 and a one year high of $3.59. The company has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $1.82. The firm has a market capitalization of $19.11 million, a PE ratio of -1.69 and a beta of 0.96.

NanoViricides (NYSE:NNVC) last announced its quarterly earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01.

Institutional Trading of NanoViricides

Several institutional investors have recently modified their holdings of NNVC. Renaissance Technologies LLC raised its position in shares of NanoViricides by 20.8% during the second quarter. Renaissance Technologies LLC now owns 102,100 shares of the company’s stock worth $176,000 after purchasing an additional 17,600 shares during the period. Integrated Wealth Concepts LLC raised its holdings in NanoViricides by 44.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 53,335 shares of the company’s stock worth $80,000 after buying an additional 16,500 shares during the period. Finally, Moss Adams Wealth Advisors LLC purchased a new stake in NanoViricides during the second quarter valued at about $26,000. Institutional investors and hedge funds own 10.30% of the company’s stock.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.